Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Darunavir Therapy in HIV
NCT03101644Phase 4Completed
- Sponsor
- UCLouvain
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by UCLouvain. Primary endpoints: Darunavir clearance up to 18 months, Darunavir volume of distribution up to 18 months and 3 more. Started Mar 2017; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03101644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101644.